[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594469":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":71,"collaborators":73,"id":78,"slug":10,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":10,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":10,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Indeterminate Lesions Cohort (Diagnosis Focus)",null,"Participants in this cohort have liver lesions categorized as LI-RADS 3 or 4 based on standard imaging. The purpose of the PSMA PET\u002FCT is to assist in the further characterization of these indeterminate nodules and support diagnosis of HCC or benign pathology.",{"label":13,"type":10,"description":14,"interventionNames":10},"Treatment-Naïve Cohort (Staging Focus)","This cohort includes participants with newly diagnosed HCC who have not yet received any locoregional or systemic therapy. PSMA PET\u002FCT is performed to evaluate the extent of disease and detect potential intrahepatic or extrahepatic spread, contributing to improved staging accuracy.",{"label":16,"type":10,"description":17,"interventionNames":10},"Post-Treatment Cohort (Treatment Response Focus)","Participants in this cohort have previously undergone locoregional therapy (e.g., TACE, RFA, or ablation). PSMA PET\u002FCT is used to assess residual or recurrent disease and help evaluate treatment response compared to standard imaging.",[19],{"name":20,"affiliation":21,"role":22},"Binu V John, MD MPH","Miami VA Healthcare System, Miami, FL","PRINCIPAL_INVESTIGATOR",[24,29],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","(305) 575-7000","17647","binu.john@va.gov",{"name":30,"role":25,"phone":31,"phoneExt":10,"email":32},"Flavia R Carneiro, PhD","(305) 575-7762","flavia.carneiro@va.gov",[34,58],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"VA Greater Los Angeles Healthcare System, West Los Angeles, CA","RECRUITING","West Los Angeles","California","90073-1003","United States",{"type":42,"coordinates":43},"Point",[44,45],-118.43068,34.0462,{"lat":45,"lon":44},[48,53],{"name":49,"role":25,"phone":50,"phoneExt":51,"email":52},"Anthony Bejjani, MD","(31-0) -3711","3023","anthony.bejjani@va.gov",{"name":54,"role":25,"phone":55,"phoneExt":56,"email":57},"Samantha Tran, BS","310 4783711","4917","samantha.tran@va.gov",{"facility":21,"status":36,"city":59,"state":60,"zip":61,"country":40,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Miami","Florida","33125",{"type":42,"coordinates":63},[64,65],-80.19366,25.77427,{"lat":65,"lon":64},[68,69,70],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},{"name":30,"role":25,"phone":31,"phoneExt":10,"email":32},{"name":20,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[74,76],{"name":75,"class":6},"Miami VA Healthcare System",{"name":77,"class":6},"VA Medical Center-West Los Angeles","100594469",false,"NCT07019844","PSMA PET for the Staging and Management of Hepatocellular Carcinoma","Addition of F18-Piflufolastat PET\u002FCT to Cross-Sectional Imaging for the Staging and Management of Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Adult patients age \\>18 years from the VA medical system\n* Treatment-naïve patients with HCC with BCLC B or C disease\n\nExclusion Criteria:\n\n* Patients with renal dysfunction or contrast allergy that precludes contrast enhanced cross sectional imaging\n* Patients with presence of active primary malignancy other than HCC and non-melanoma skin cancer in the past 3 years","ALL","18 Years",{"count":87,"type":88},90,"ESTIMATED","OBSERVATIONAL","This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET\u002FCT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET\u002FCT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET\u002FCT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.",[92],"Hepatocellular Carcinoma (HCC)","2026-06-23",{"date":95,"type":96},"2026-06-26","ACTUAL",{"date":98,"type":96},"2024-09-19",{"date":100,"type":88},"2028-09-30",{"name":5,"class":6},2]